Literature DB >> 32589076

Urgent Appeal from International Society for Aerosols in Medicine (ISAM) During COVID-19: Clinical Decision Makers and Governmental Agencies Should Consider the Inhaled Route of Administration: A Statement from the ISAM Regulatory and Standardization Issues Networking Group.

Jolyon P Mitchell1, Ariel Berlinski2, Sebastian Canisius3, David Cipolla4, Myrna B Dolovich5, Igor Gonda6, Guenther Hochhaus7, Nani Kadrichu8, Svetlana Lyapustina9, Heidi M Mansour10, Chantal Darquenne11, Andy R Clark12, Michael Newhouse13,14, Stephan Ehrmann15, Robert Humphries16, Homer Boushey17.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32589076     DOI: 10.1089/jamp.2020.1622

Source DB:  PubMed          Journal:  J Aerosol Med Pulm Drug Deliv        ISSN: 1941-2711            Impact factor:   2.849


× No keyword cloud information.
  13 in total

Review 1.  Current Opinion on the Therapeutic Capacity of Taurine-Containing Halogen Derivatives in Infectious and Inflammatory Diseases.

Authors:  Janusz Marcinkiewicz; Markus Nagl; Anthony Kyriakopoulos; Maria Walczewska; Magdalena Skóra; Paulina Skalska
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

Review 2.  Inhaled therapy for COVID-19: Considerations of drugs, formulations and devices.

Authors:  Tushar Saha; Miguel E Quiñones-Mateu; Shyamal C Das
Journal:  Int J Pharm       Date:  2022-07-20       Impact factor: 6.510

Review 3.  Pulmonary drug delivery: an effective and convenient delivery route to combat COVID-19.

Authors:  Shohreh Alipour; Laleh Mahmoudi; Fatemeh Ahmadi
Journal:  Drug Deliv Transl Res       Date:  2022-10-19       Impact factor: 5.671

Review 4.  A Narrative Review of a Pulmonary Aerosolized Formulation or a Nasal Drop Using Sera Containing Neutralizing Antibodies Collected from COVID-19-Recovered Patients as a Probable Therapy for COVID-19.

Authors:  Nishat Fatima; Vichitra Kaushik; Amjad Ayoub
Journal:  Iran J Med Sci       Date:  2021-05

Review 5.  Recent updates in COVID-19 with emphasis on inhalation therapeutics: Nanostructured and targeting systems.

Authors:  Ahmed A H Abdellatif; Hesham M Tawfeek; Ahmed Abdelfattah; Gaber El-Saber Batiha; Helal F Hetta
Journal:  J Drug Deliv Sci Technol       Date:  2021-02-19       Impact factor: 3.981

Review 6.  Nasally inhaled therapeutics and vaccination for COVID-19: Developments and challenges.

Authors:  Jinxiang Xi; Lameng Ray Lei; William Zouzas; Xiuhua April Si
Journal:  MedComm (2020)       Date:  2021-12-14

7.  N-chlorotaurine is highly active against respiratory viruses including SARS-CoV-2 (COVID-19) in vitro.

Authors:  Michaela Lackner; Annika Rössler; André Volland; Marlena Nastassja Stadtmüller; Brigitte Müllauer; Zoltan Banki; Johannes Ströhle; Angela Luttick; Jennifer Fenner; Bettina Sarg; Leopold Kremser; Paul Tone; Heribert Stoiber; Dorothee von Laer; Thorsten Wolff; Carsten Schwarz; Markus Nagl
Journal:  Emerg Microbes Infect       Date:  2022-12       Impact factor: 19.568

Review 8.  Inhalation Delivery for the Treatment and Prevention of COVID-19 Infection.

Authors:  Basanth Babu Eedara; Wafaa Alabsi; David Encinas-Basurto; Robin Polt; Julie G Ledford; Heidi M Mansour
Journal:  Pharmaceutics       Date:  2021-07-14       Impact factor: 6.525

Review 9.  Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management.

Authors:  Vivek P Chavda; Lalitkumar K Vora; Anjali K Pandya; Vandana B Patravale
Journal:  Drug Discov Today       Date:  2021-07-29       Impact factor: 7.851

10.  Chasing COVID-19 chemotherapeutics without putting the cart before the horse.

Authors:  Steven P Rannard; Tom O McDonald; Andrew Owen
Journal:  Br J Clin Pharmacol       Date:  2020-11-20       Impact factor: 3.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.